L
Lissun connects individuals with mental health professionals via online and offline services, plus self-help tools and corporate wellness programs.
$5KSeries A
All funding news
Healthtech funding news
4 recent Healthtech rounds across our tracked sources.
Mykare builds an AI operating system for hospitals to automate patient scheduling, acquisition, and feedback collection via voice agents.
$3.2MSeed
Investor undisclosed
A $3.2M seed for hospital ops automation signals that AI voice agents are finally moving past chatbots into revenue-touching workflows—this is about replacing FTEs, not just deflecting support tickets. If you're building in adjacent healthcare operations (billing, discharge, referral workflows), the fact that Mykare landed Andrew Parker + a Middle Eastern family office suggests there's real appetite for India-first healthtech that solves acute labor shortages, not just US-market problems.
Alan builds a digital health insurance platform combining coverage and healthcare services for individuals and businesses.
$523.2MSeries G
A $523M Series G for a European health insurance platform signals that vertical integration (insurance + care delivery) is now fundable at scale—Prosus betting on Alan suggests the unit economics work when you own both sides. If you're building in adjacent verticals (dental, mental health, pet insurance), this validates the playbook: raise big, lock in supply-side partnerships, and use capital to compress claims cycles. Watch whether Alan's next move is geographic expansion or adjacent verticals—that'll tell you if this model scales beyond France.
4baseCare combines genomics and AI to deliver personalized cancer treatment plans based on patient genetic and clinical data.
$0Series B
A $0M Series B is either a data error or a bridge round—either way, it signals growX is backing the precision oncology thesis in India, where genomics infrastructure is still nascent but labor costs make the unit economics work. If you're building in adjacent diagnostic verticals (rare disease, pharmacogenomics), watch whether 4baseCare can actually move the needle on treatment outcomes; that's the moat that matters, not just the AI wrapper.